Erxiekang emplastra as adjunctive therapy for acute gastroenteritis in children: a single-center retrospective cohort study - Takeaways - MDSpire

Erxiekang emplastra as adjunctive therapy for acute gastroenteritis in children: a single-center retrospective cohort study

  • By

  • Cuiyun Fang

  • Yuan Zhou

  • Zhongli Jiang

  • Xiaoxue Su

  • Wei Fan

  • June 11, 2026

  • 0 min

Share

  • 1

    The study evaluated Erxiekang Emplastra as an adjunctive treatment for acute gastroenteritis in children aged 1 to 14 years.

  • 2

    A total of 1,089 pediatric patients were analyzed, with 417 receiving Erxiekang Emplastra and 672 receiving standard therapy alone.

  • 3

    The exposed group showed significantly shorter diarrhea duration (3.83 vs. 4.92 days, p < 0.01) and lower 3-day Modified Vesikari Scale scores.

  • 4

    Only 1.44% of patients experienced mild transient local reactions, with no severe adverse events reported.

  • 5

    The study suggests that Erxiekang Emplastra may improve outcomes in pediatric acute gastroenteritis, warranting further research.

Original Source(s)

Erxiekang emplastra as adjunctive therapy for acute gastroenteritis in children: a single-center retrospective cohort study

  • by Cuiyun Fang, Yuan Zhou, Zhongli Jiang, Xiaoxue Su, Wei Fan

  • June 11, 2026

Related Content

Social connectedness in mobile gaming: how family dynamics shape children’s virtual interactions

Unexpected genetically determined immune dysregulation with liver involvement: GIMAP5 therapeutic dilemmas between targeted therapy and HSCT

Choroidal structural and perfusion characteristics across refractive groups in children